Dequeker J, Gevers G
Scand J Rheumatol Suppl. 1986;63:85-95.
An open study in Belgium assessed the clinical efficacy and safety of auranofin (AF) in treating psoriatic arthritis. The study enrolled 29 patients; median age was 46 years and median duration of disease was 5.5 years. Patients received 6 mg AF daily, given as two 3-mg tablets once a day. Concomitant therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids was permitted. Efficacy of auranofin was apparent by 3 months after the start of treatment, as evidenced by improvement over baseline in number of tender joints, severity of pain, and erythrocyte sedimentation rate. After 1 year of auranofin therapy there was 50% or greater improvement over baseline in these parameters in 11% to 41% of the total population, and in 19% to 69% of those who completed at least 1 year of treatment. Diarrhea was reported in 45% of patients, occurring most often during the first 6 months of therapy. Nausea occurred in 10%; abdominal pain in 7%; rash in 14%; and pruritus in 17%. Withdrawals because of adverse events totaled 4: 1 for rash, 2 for pruritus, and 1 for rash, pruritus, and purpura. Auranofin may be considered an effective and safe therapeutic alternative for the treatment of psoriatic arthritis.
比利时的一项开放性研究评估了金诺芬（AF）治疗银屑病关节炎的临床疗效和安全性。该研究招募了29名患者；中位年龄为46岁，疾病中位病程为5.5年。患者每天服用6毫克金诺芬，以两片3毫克片剂的形式，每天服用一次。允许同时使用非甾体抗炎药（NSAIDs）和皮质类固醇进行治疗。治疗开始3个月后，金诺芬的疗效明显，表现为压痛关节数量、疼痛严重程度和红细胞沉降率较基线有所改善。金诺芬治疗1年后，在全部患者中，11%至41%的患者在这些参数上较基线改善了50%或更多，在至少完成1年治疗的患者中，这一比例为19%至69%。45%的患者报告有腹泻，最常发生在治疗的前6个月。10%的患者出现恶心；7%出现腹痛；14%出现皮疹；17%出现瘙痒。因不良事件而停药的共有4例：1例因皮疹，2例因瘙痒，1例因皮疹、瘙痒和紫癜。金诺芬可被视为治疗银屑病关节炎的一种有效且安全的治疗选择。
